AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Feb 3, 2021
31637_dirs_2021-02-02_e890bbfd-c0f3-4b43-9606-e6bb7ac922f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-02-01
Reporting Person: Watts Ryan J. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-01 | Common Stock | S | 14222 | $68.212 | Disposed | 2308761 | Indirect |
| 2021-02-01 | Common Stock | S | 3552 | $69.167 | Disposed | 2305209 | Indirect |
| 2021-02-01 | Common Stock | S | 560 | $69.69 | Disposed | 2304649 | Indirect |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.63 to $68.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.64 to $69.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.